Insider Transactions for HALOZYME THERAPEUTICS, INC.

Helen Torley, President and CEO of HALOZYME THERAPEUTICS, INC., executed a series of transactions on April 6, 2026, involving the company's Common Stock. Torley acquired 10,000 shares through the exercise of stock options at a price of $12.07 per share, increasing her post-transaction holdings to 777,780 shares. Concurrently, she disposed of shares in multiple tranches. A sale of 5,900 shares occurred at a weighted average price of $63.139, with shares sold ranging from $62.710 to $63.670, leaving 771,880 shares. Another sale involved 4,100 shares at a weighted average price of $64.015, with prices ranging from $63.750 to $64.330, resulting in 767,780 shares. Additionally, Torley exercised options to purchase 10,000 shares of Common Stock, with the options expiring in February 2027. All transactions were made under a Rule 10b5-1 trading plan adopted on March 21, 2025.